<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/CDEDC9AA-78F1-492E-9F1E-30F59AF1C090"><gtr:id>CDEDC9AA-78F1-492E-9F1E-30F59AF1C090</gtr:id><gtr:name>MRC Centre for Protein Engineering</gtr:name><gtr:address><gtr:line1>Hills Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 2QH</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/CDEDC9AA-78F1-492E-9F1E-30F59AF1C090"><gtr:id>CDEDC9AA-78F1-492E-9F1E-30F59AF1C090</gtr:id><gtr:name>MRC Centre for Protein Engineering</gtr:name><gtr:address><gtr:line1>Hills Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 2QH</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/B6F90BFD-2660-441C-A2C4-51EC8ECB6A4C"><gtr:id>B6F90BFD-2660-441C-A2C4-51EC8ECB6A4C</gtr:id><gtr:firstName>Alan</gtr:firstName><gtr:surname>fersht</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_U105474168"><gtr:id>B6970954-B32C-4CA6-9F50-B05466387932</gtr:id><gtr:title>Cancer and Mutational Diseases</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_U105474168</gtr:grantReference><gtr:abstractText>An execution squad of proteins, led by p53, defends the body against cancer. Unfortunately the troops are fragile and p53 and its subordinates are easily incapacitated by mutations caused by the environment or inherited. Over 50% of human cancers have suffered direct inactivation of their p53, and most of the rest have had other members of the team incapacitated. Radiotherapy and standard chemotherapy kill cancerous cells by galvanizing p53 into action. So, the loss of p53 not only removes the bodys natural defences but also causes resistance to much conventional therapy. We have found that in half of the cases where p53 is inactive it is in fact only injured, and so could in theory be reactivated by chemical drugs. We have designed a molecular splint to do this that works in the test tube and has promising results in cancer cells. Our molecule does reactivate mutant p53, which then partly sets in action the cells killing squad of proteins. About one in six of the population develops a mutation in p53 putting them at risk of cancer, and so the possibility of reactivating many of these mutants would be very important. Our compound could be a lead for development of novel anti-cancer drugs that may be effective by themselves, or in conjunction with conventional treatments.</gtr:abstractText><gtr:technicalSummary>Cancer is caused by mutations that lead to the malfunction of proteins that control the cell cycle. A key protein is the tumour suppressor p53 that senses lesions that may lead to cancer and then stops cells dividing and directs them to programmed death. p53 is directly inactivated by mutation in some 50% of cancers. p53 is a transcription factor that turns on many genes and is at the centre of a network of interacting pathways that determine cell growth, arrest and death. p53-associated pathways are disrupted in the remaining 50% of cancers. A current strategy of cancer therapy is to attempt to reactivate p53 and its associated pathways in cancer cells. Our goals are to analyse the structure and function of p53 and how its activity is modulated by the binding of ligands and affected by mutation. We shall investigate the possibilities of rescuing oncogenic mutants of p53 by small molecules that bind to p53, with the aim of producing leads for novel anti-cancer drugs. We shall develop our recently discovered first lead compound, the peptide FL-CDB3, which rescues oncogenic mutants of p53 in vitro and has promising activity in living cancer cells. We shall determine the high-resolution structure and dynamic properties of the mutationally sensitive DNA binding domain of p53 by x-ray crystallography and NMR, with wild-type p53 and a superstable mutant. We shall determine the structural consequences of mutation using our superstable mutant as the template. We shall analyse the binding of DNA promoters to the core domain. These studies will be extended to progressively larger constructs of p53 fragments and to full-length protein. We shall analyse the interactions of the constructs with other proteins. We shall synthesise peptides based on proteins that interact with p53 and determine their mode of interaction with p53 constructs by NMR and investigate the effects of these peptides on the stability and activity of p53 in vitro. We shall then collaborate with cell biologists to investigate the effects in cancer cell lines and in mice. We shall screen for the binding of ligands to p53 by NMR and other methods. We shall extend our structural studies to other proteins in the cell cycle that interact with p53, beginning with MDM2, the key regulator of its level in cells. In the future, cancer may be managed by cocktails of drugs that control the cell cycle. Our studies will underpin such therapy and may lead directly to novel drugs.</gtr:technicalSummary><gtr:fund><gtr:end>2010-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>1999-01-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>9074447</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Radio Broadcast in Australia</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>D44C3463-6F23-4EF4-972A-D932E7FEACD7</gtr:id><gtr:impact>I gave a talk for the COMBIO 2008 conference in Canberra. The Australian's liked my lecture so much that the press and radio joined in afterwards. I first had to dictate an article for a Sunday newspaper and then give a radio interview and answer some phone-in questions.

Article in Canberra Times</gtr:impact><gtr:outcomeId>FD052AACD23</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invited Special Lecturer to graduate students in Cambridge, USA, Switzerland and Germany</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>54B64756-0E01-4AB8-B63D-FA9CFFDB70BF</gtr:id><gtr:impact>I have given lectures to graduate students in Cambridge, USA, Switzerland and Germany

Excellent feedback from students</gtr:impact><gtr:outcomeId>4A208AA284F</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>We are developing novel anti-cancer drugs that function by reactivating the tumour suppressor p53.</gtr:description><gtr:grantRef>MC_U105474168</gtr:grantRef><gtr:id>BE2A6ECB-0BA4-4FE6-A0BC-96E8BFCCB631</gtr:id><gtr:impact>In progress</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>2C96B7000BD</gtr:outcomeId><gtr:patentId>WO2009136175</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>p53 Binding Sites</gtr:title><gtr:yearProtectionGranted>2009</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>We are developing novel anti-cancer drugs that function by reactivating the tumour suppressor p53</gtr:description><gtr:grantRef>MC_U105474168</gtr:grantRef><gtr:id>BA5A4ABF-BC92-421B-836E-554D68F4A3D3</gtr:id><gtr:impact>In progress</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>56CB42AEB8D</gtr:outcomeId><gtr:patentId>US2010130731</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>p53 Mutants</gtr:title><gtr:yearProtectionGranted>2010</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:description>We are developing novel anti-cancer drugs that function by reactivating the tumour suppressor p53</gtr:description><gtr:id>38A7AEB5-6A92-443E-89B0-3EA2730CAB8E</gtr:id><gtr:impact>In progress</gtr:impact><gtr:outcomeId>737F1DD9CFD</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>p53 Reactivating Drug</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2008</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>A cell line that is used for our assays and is currently unpublished</gtr:description><gtr:id>3E8BFE6B-CC71-4BA5-9835-1E338792DF25</gtr:id><gtr:impact>None</gtr:impact><gtr:outcomeId>B6C95C3F3DF</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Cell Line</gtr:title><gtr:type>Cell line</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>05DD621C-C1E3-4C4B-AA80-70B19D2E3D92</gtr:id><gtr:title>Four domains of p300 each bind tightly to a sequence spanning both transactivation subdomains of p53.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/56d3523d2f7264b44eb37e799be70d5e"><gtr:id>56d3523d2f7264b44eb37e799be70d5e</gtr:id><gtr:otherNames>Teufel DP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>B818BCE9126</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>47FB078C-1268-455A-B492-3CAD27A60FB6</gtr:id><gtr:title>Effects of common cancer mutations on stability and DNA binding of full-length p53 compared with isolated core domains.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/588f3ad880d3fb3d2648b655eeea5fc9"><gtr:id>588f3ad880d3fb3d2648b655eeea5fc9</gtr:id><gtr:otherNames>Ang HC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>7DC34B7E267</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7120D0A5-0D2A-4A1E-BAC9-F76301FE46AD</gtr:id><gtr:title>The novel p53 isoform &amp;quot;delta p53&amp;quot; is a misfolded protein and does not bind the p21 promoter site.</gtr:title><gtr:parentPublicationTitle>Protein science : a publication of the Protein Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ff4c9467962ce49d0091fb734f4937f9"><gtr:id>ff4c9467962ce49d0091fb734f4937f9</gtr:id><gtr:otherNames>Garc?a-Alai MM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0961-8368</gtr:issn><gtr:outcomeId>D5C126FC594</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5E861532-2A2C-460C-8D81-518F029E8A9D</gtr:id><gtr:title>Phosphotriesterase variants with high methylphosphonatase activity and strong negative trade-off against phosphotriesters.</gtr:title><gtr:parentPublicationTitle>Protein engineering, design &amp; selection : PEDS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5611a8866272c43f1905aa8757afe23f"><gtr:id>5611a8866272c43f1905aa8757afe23f</gtr:id><gtr:otherNames>Brise?o-Roa L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1741-0126</gtr:issn><gtr:outcomeId>KEAwAjjX5p2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8DC5D2B1-2A1B-465A-B20F-F2BBE2D94BB2</gtr:id><gtr:title>Energy-dependent nucleolar localization of p53 in vitro requires two discrete regions within the p53 carboxyl terminus.</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/46b0e3760e8e5086697243fcc6ea887e"><gtr:id>46b0e3760e8e5086697243fcc6ea887e</gtr:id><gtr:otherNames>Karni-Schmidt O</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn><gtr:outcomeId>EF91418E42A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>488C819A-DF5A-48BE-A280-1547E12951A4</gtr:id><gtr:title>Quaternary structures of tumor suppressor p53 and a specific p53 DNA complex.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/90e7550fe9645a0e247f86ca08f6b8d7"><gtr:id>90e7550fe9645a0e247f86ca08f6b8d7</gtr:id><gtr:otherNames>Tidow H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>7EA5370F195</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>83EC5561-2575-4CD7-AB18-C5D3DA363445</gtr:id><gtr:title>Stabilization of mutant p53 via alkylation of cysteines and effects on DNA binding.</gtr:title><gtr:parentPublicationTitle>Protein science : a publication of the Protein Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/da1eaba6bed9d6e448f216bb9ba892da"><gtr:id>da1eaba6bed9d6e448f216bb9ba892da</gtr:id><gtr:otherNames>Kaar JL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0961-8368</gtr:issn><gtr:outcomeId>dHY295kvJ4B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DB77EE79-B548-4A96-907D-7E41A5DFEB3F</gtr:id><gtr:title>Highest paraoxonase turnover rate found in a bacterial phosphotriesterase variant.</gtr:title><gtr:parentPublicationTitle>Protein engineering, design &amp; selection : PEDS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5611a8866272c43f1905aa8757afe23f"><gtr:id>5611a8866272c43f1905aa8757afe23f</gtr:id><gtr:otherNames>Brise?o-Roa L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1741-0126</gtr:issn><gtr:outcomeId>SCLeReA5Eet</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E6FE800A-F7E7-40EC-B229-C8100BCC163A</gtr:id><gtr:title>Mapping the physical and functional interactions between the tumor suppressors p53 and BRCA2.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ccb7ce23248b9a7772ca8f20bdf48a1d"><gtr:id>ccb7ce23248b9a7772ca8f20bdf48a1d</gtr:id><gtr:otherNames>Rajagopalan S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>mSH4FEtiB34</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C2414519-542B-4C9B-9140-5006215F3AB4</gtr:id><gtr:title>Molecular basis of the interactions between the p73 N terminus and p300: effects on transactivation and modulation by phosphorylation.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bdcc13aec80cb642c8b33a1586fc256b"><gtr:id>bdcc13aec80cb642c8b33a1586fc256b</gtr:id><gtr:otherNames>Burge S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>36CFB29A760</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>293CC601-12B7-4E32-8C05-F0C986E37E67</gtr:id><gtr:title>Regulation by phosphorylation of the relative affinities of the N-terminal transactivation domains of p53 for p300 domains and Mdm2.</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/56d3523d2f7264b44eb37e799be70d5e"><gtr:id>56d3523d2f7264b44eb37e799be70d5e</gtr:id><gtr:otherNames>Teufel DP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn><gtr:outcomeId>CD975207D6B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ACD7308C-CE18-4419-804D-07104390EBCD</gtr:id><gtr:title>Stabilising the DNA-binding domain of p53 by rational design of its hydrophobic core.</gtr:title><gtr:parentPublicationTitle>Protein engineering, design &amp; selection : PEDS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b4f2fb07f94106152c1169e01a66a916"><gtr:id>b4f2fb07f94106152c1169e01a66a916</gtr:id><gtr:otherNames>Khoo KH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1741-0126</gtr:issn><gtr:outcomeId>0DCD2622A61</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1E9E9DF0-6F91-486E-8388-8B9CCBBB8A2A</gtr:id><gtr:title>Modulation of the oligomerization state of p53 by differential binding of proteins of the S100 family to p53 monomers and tetramers.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fed8a6b1fc4d80dfac884b38e5943779"><gtr:id>fed8a6b1fc4d80dfac884b38e5943779</gtr:id><gtr:otherNames>van Dieck J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>07B488BD01F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>34A11146-C79D-4C8D-ACFA-D9AF5DC258C5</gtr:id><gtr:title>Structural evolution of p53, p63, and p73: implication for heterotetramer formation.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/daa11163c118bd701c4a98f87e5a2378"><gtr:id>daa11163c118bd701c4a98f87e5a2378</gtr:id><gtr:otherNames>Joerger AC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>L7MpvUhkfoa</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B21FE2DE-665A-4388-AD66-929AB958903B</gtr:id><gtr:title>Mechanistic differences in the transcriptional activation of p53 by 14-3-3 isoforms.</gtr:title><gtr:parentPublicationTitle>Nucleic acids research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ccb7ce23248b9a7772ca8f20bdf48a1d"><gtr:id>ccb7ce23248b9a7772ca8f20bdf48a1d</gtr:id><gtr:otherNames>Rajagopalan S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0305-1048</gtr:issn><gtr:outcomeId>sk4tnfwqXL2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>89C6E41F-F501-4E3F-B1DA-D8E6FD26EF13</gtr:id><gtr:title>Comparative biophysical characterization of p53 with the pro-apoptotic BAK and the anti-apoptotic BCL-xL.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/078d0719a881134b6ddd92ce45e4527d"><gtr:id>078d0719a881134b6ddd92ce45e4527d</gtr:id><gtr:otherNames>Sot B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>AB811C5B78E</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>768DF9A9-C54C-444E-B5C2-094157FC0598</gtr:id><gtr:title>Algorithm for prediction of tumour suppressor p53 affinity for binding sites in DNA.</gtr:title><gtr:parentPublicationTitle>Nucleic acids research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aa8049e365b925ab0549f545b54d1189"><gtr:id>aa8049e365b925ab0549f545b54d1189</gtr:id><gtr:otherNames>Veprintsev DB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0305-1048</gtr:issn><gtr:outcomeId>7DE4D570053</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1AED8C97-735C-4EE1-9696-91AF1C1AE152</gtr:id><gtr:title>Targeted rescue of a destabilized mutant of p53 by an in silico screened drug.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1b5e8da8f25bd17565abaee7f98410e4"><gtr:id>1b5e8da8f25bd17565abaee7f98410e4</gtr:id><gtr:otherNames>Boeckler FM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>53ADCC92788</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E15B4645-BA6F-495B-9FDC-DE2BA6B98C44</gtr:id><gtr:title>Effects of stability on the biological function of p53.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b4f2fb07f94106152c1169e01a66a916"><gtr:id>b4f2fb07f94106152c1169e01a66a916</gtr:id><gtr:otherNames>Khoo KH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>B9D3360E7C0</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>887ED98D-9FD0-4E0F-AA79-2730915927ED</gtr:id><gtr:title>Members of the S100 family bind p53 in two distinct ways.</gtr:title><gtr:parentPublicationTitle>Protein science : a publication of the Protein Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3d6a101c948f04d68ec7ad00491ddf9b"><gtr:id>3d6a101c948f04d68ec7ad00491ddf9b</gtr:id><gtr:otherNames>Fernandez-Fernandez MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0961-8368</gtr:issn><gtr:outcomeId>E425B5CE54E</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>842B8B85-FD0C-476C-9979-EC8E6FE5FD8C</gtr:id><gtr:title>S100 proteins interact with the N-terminal domain of MDM2.</gtr:title><gtr:parentPublicationTitle>FEBS letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fed8a6b1fc4d80dfac884b38e5943779"><gtr:id>fed8a6b1fc4d80dfac884b38e5943779</gtr:id><gtr:otherNames>van Dieck J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0014-5793</gtr:issn><gtr:outcomeId>VFc7bmZ1EwQ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>46683CF9-170C-42E5-AFD2-92C41C96E785</gtr:id><gtr:title>Interaction between the transactivation domain of p53 and PC4 exemplifies acidic activation domains as single-stranded DNA mimics.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ccb7ce23248b9a7772ca8f20bdf48a1d"><gtr:id>ccb7ce23248b9a7772ca8f20bdf48a1d</gtr:id><gtr:otherNames>Rajagopalan S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>CD6894645E6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>13DCEF3A-B604-4CA2-A21E-571ED05244CA</gtr:id><gtr:title>Multiple conformations of full-length p53 detected with single-molecule fluorescence resonance energy transfer.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1fb7adef0ce22657c6ddda02c27fcffb"><gtr:id>1fb7adef0ce22657c6ddda02c27fcffb</gtr:id><gtr:otherNames>Huang F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>nDf2kWjEQxH</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BFEB93E1-4B4B-4E06-A006-C2E32D1FCF98</gtr:id><gtr:title>Adaptive evolution of p53 thermodynamic stability.</gtr:title><gtr:parentPublicationTitle>Journal of molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b4f2fb07f94106152c1169e01a66a916"><gtr:id>b4f2fb07f94106152c1169e01a66a916</gtr:id><gtr:otherNames>Khoo KH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-2836</gtr:issn><gtr:outcomeId>7EE5E54E067</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CE40FB52-EDA8-4900-AC45-7AE66D8582CA</gtr:id><gtr:title>Solution structure of the U11-48K CHHC zinc-finger domain that specifically binds the 5' splice site of U12-type introns.</gtr:title><gtr:parentPublicationTitle>Structure (London, England : 1993)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/90e7550fe9645a0e247f86ca08f6b8d7"><gtr:id>90e7550fe9645a0e247f86ca08f6b8d7</gtr:id><gtr:otherNames>Tidow H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0969-2126</gtr:issn><gtr:outcomeId>646B6360515</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8DBDBCAA-0A9B-49C3-96E7-3F36F928EB18</gtr:id><gtr:title>Structure of human MDM4 N-terminal domain bound to a single-domain antibody.</gtr:title><gtr:parentPublicationTitle>Journal of molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5160dbb6f1bcb254474424a7acc5532c"><gtr:id>5160dbb6f1bcb254474424a7acc5532c</gtr:id><gtr:otherNames>Yu GW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-2836</gtr:issn><gtr:outcomeId>5AF7F55B5F5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>469A0230-DFE6-4857-A5FD-75F6C25E2534</gtr:id><gtr:title>Ultraslow oligomerization equilibria of p53 and its implications.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2cb10fc9c59c4712409caddcf226407a"><gtr:id>2cb10fc9c59c4712409caddcf226407a</gtr:id><gtr:otherNames>Natan E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>0B8E6071B8C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F4BED8C2-9828-4C68-9D9F-E3C8C9198019</gtr:id><gtr:title>The central region of HDM2 provides a second binding site for p53.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5160dbb6f1bcb254474424a7acc5532c"><gtr:id>5160dbb6f1bcb254474424a7acc5532c</gtr:id><gtr:otherNames>Yu GW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>F6E91876D91</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B7A99C56-79E6-4DC9-8051-D810FC515837</gtr:id><gtr:title>Correlation of levels of folded recombinant p53 in escherichia coli with thermodynamic stability in vitro.</gtr:title><gtr:parentPublicationTitle>Journal of molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/10d09bca4a8b31350c698a4882055f5a"><gtr:id>10d09bca4a8b31350c698a4882055f5a</gtr:id><gtr:otherNames>Mayer S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-2836</gtr:issn><gtr:outcomeId>0AE43441AF7</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C1FCD6DB-91E1-46CC-90C0-93CF8F50CB3D</gtr:id><gtr:title>Single-Molecule characterization of oligomerization kinetics and equilibria of the tumor suppressor p53.</gtr:title><gtr:parentPublicationTitle>Nucleic acids research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ccb7ce23248b9a7772ca8f20bdf48a1d"><gtr:id>ccb7ce23248b9a7772ca8f20bdf48a1d</gtr:id><gtr:otherNames>Rajagopalan S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0305-1048</gtr:issn><gtr:outcomeId>ZL3ksn18fYn</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>63938AD6-78A5-468A-A78F-D9DFC4AF61C5</gtr:id><gtr:title>Structure of tumor suppressor p53 and its intrinsically disordered N-terminal transactivation domain.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fc8c8165a2fbd044da6092ba349cac76"><gtr:id>fc8c8165a2fbd044da6092ba349cac76</gtr:id><gtr:otherNames>Wells M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>93221E274CA</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AE49BDF1-43D9-415D-9262-B3ABD7703FD4</gtr:id><gtr:title>Core domain interactions in full-length p53 in solution.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aa8049e365b925ab0549f545b54d1189"><gtr:id>aa8049e365b925ab0549f545b54d1189</gtr:id><gtr:otherNames>Veprintsev DB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>E1FA674B99B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BBDD6C0C-584F-4726-BFC0-F741895164BA</gtr:id><gtr:title>The accessory subunit of mitochondrial DNA polymerase gamma determines the DNA content of mitochondrial nucleoids in human cultured cells.</gtr:title><gtr:parentPublicationTitle>Nucleic acids research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e14896acad9391ba6555da56a556356a"><gtr:id>e14896acad9391ba6555da56a556356a</gtr:id><gtr:otherNames>Di Re M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0305-1048</gtr:issn><gtr:outcomeId>jzSp9T4JV6b</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DCBEF852-CB4A-410B-B529-911DDC88301A</gtr:id><gtr:title>Effects of oncogenic mutations and DNA response elements on the binding of p53 to p53-binding protein 2 (53BP2).</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/90e7550fe9645a0e247f86ca08f6b8d7"><gtr:id>90e7550fe9645a0e247f86ca08f6b8d7</gtr:id><gtr:otherNames>Tidow H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>EFD82D27E3C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F976A6F9-B6F3-4B88-8622-2BCE9C862E30</gtr:id><gtr:title>Structural basis for understanding oncogenic p53 mutations and designing rescue drugs.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/daa11163c118bd701c4a98f87e5a2378"><gtr:id>daa11163c118bd701c4a98f87e5a2378</gtr:id><gtr:otherNames>Joerger AC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>897007CBD16</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>72AFA207-49EB-4139-8557-A27B22B67821</gtr:id><gtr:title>PRIMA-1 reactivates mutant p53 by covalent binding to the core domain.</gtr:title><gtr:parentPublicationTitle>Cancer cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/52af87497fb53afd7a1169ea4fd3a82f"><gtr:id>52af87497fb53afd7a1169ea4fd3a82f</gtr:id><gtr:otherNames>Lambert JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1535-6108</gtr:issn><gtr:outcomeId>C27A79A35F9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1D7CBC08-40DD-407F-8F35-1C5DA9D80A25</gtr:id><gtr:title>14-3-3 activation of DNA binding of p53 by enhancing its association into tetramers.</gtr:title><gtr:parentPublicationTitle>Nucleic acids research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ccb7ce23248b9a7772ca8f20bdf48a1d"><gtr:id>ccb7ce23248b9a7772ca8f20bdf48a1d</gtr:id><gtr:otherNames>Rajagopalan S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0305-1048</gtr:issn><gtr:outcomeId>810A5F63175</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D4B77359-02DE-43B7-8D75-FD140C26E897</gtr:id><gtr:title>Physical and functional interactions between human mitochondrial single-stranded DNA-binding protein and tumour suppressor p53.</gtr:title><gtr:parentPublicationTitle>Nucleic acids research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b220522c7f5643efc380ec18d4638e55"><gtr:id>b220522c7f5643efc380ec18d4638e55</gtr:id><gtr:otherNames>Wong TS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0305-1048</gtr:issn><gtr:outcomeId>086D1504DD9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BE9F2221-1B10-4762-B086-1F6084F998FB</gtr:id><gtr:title>Solution structure of the C4 zinc finger domain of HDM2.</gtr:title><gtr:parentPublicationTitle>Protein science : a publication of the Protein Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5160dbb6f1bcb254474424a7acc5532c"><gtr:id>5160dbb6f1bcb254474424a7acc5532c</gtr:id><gtr:otherNames>Yu GW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0961-8368</gtr:issn><gtr:outcomeId>0FC4E017087</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>53DC55D9-6B2C-40A7-BA2D-ADAA1E227154</gtr:id><gtr:title>Structure-function-rescue: the diverse nature of common p53 cancer mutants.</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/daa11163c118bd701c4a98f87e5a2378"><gtr:id>daa11163c118bd701c4a98f87e5a2378</gtr:id><gtr:otherNames>Joerger AC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn><gtr:outcomeId>41AFCF056E1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4DFA02FE-9C21-494F-9EC3-869ECEF45857</gtr:id><gtr:title>Toward the rational design of p53-stabilizing drugs: probing the surface of the oncogenic Y220C mutant.</gtr:title><gtr:parentPublicationTitle>Chemistry &amp; biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/80f8330bd58b973a690c05e2d1e7d018"><gtr:id>80f8330bd58b973a690c05e2d1e7d018</gtr:id><gtr:otherNames>Basse N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1074-5521</gtr:issn><gtr:outcomeId>Reszx53e7Nn</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2802EE18-C418-4BF8-B63E-7C7421342929</gtr:id><gtr:title>Solution structure of p53 core domain: structural basis for its instability.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f2114b92f3644a82c17c2dfdb3d51c64"><gtr:id>f2114b92f3644a82c17c2dfdb3d51c64</gtr:id><gtr:otherNames>Ca?adillas JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>0EC92A12C23</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3A92D9AD-4A02-4296-B640-91008BB72051</gtr:id><gtr:title>Molecular basis of S100 proteins interacting with the p53 homologs p63 and p73.</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fed8a6b1fc4d80dfac884b38e5943779"><gtr:id>fed8a6b1fc4d80dfac884b38e5943779</gtr:id><gtr:otherNames>van Dieck J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn><gtr:outcomeId>ETYuBR3zPrD</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E34922E1-9F4C-4C8B-BE48-F3D13AA4CAFF</gtr:id><gtr:title>Analogues with fluorescent leaving groups for screening and selection of enzymes that efficiently hydrolyze organophosphorus nerve agents.</gtr:title><gtr:parentPublicationTitle>Journal of medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5611a8866272c43f1905aa8757afe23f"><gtr:id>5611a8866272c43f1905aa8757afe23f</gtr:id><gtr:otherNames>Brise?o-Roa L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0022-2623</gtr:issn><gtr:outcomeId>CAB990CBB57</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C52F4F6C-D805-4D31-9311-AAF9FCE7EB5F</gtr:id><gtr:title>Solution structure of ASPP2 N-terminal domain (N-ASPP2) reveals a ubiquitin-like fold.</gtr:title><gtr:parentPublicationTitle>Journal of molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/90e7550fe9645a0e247f86ca08f6b8d7"><gtr:id>90e7550fe9645a0e247f86ca08f6b8d7</gtr:id><gtr:otherNames>Tidow H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-2836</gtr:issn><gtr:outcomeId>961DF4BAEB4</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_U105474168</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>